Literature DB >> 2941596

Rifampin protection against experimental graft sepsis.

E G McDougal, S J Burnham, G Johnson.   

Abstract

The risk of infection in vascular prosthetic conduits appears to be greatest in the perioperative period and the organism most frequently found is Staphylococcus aureus. Previous work suggests that antibiotics must be chemically bonded to the material to resist rapid washout caused by the flow of blood through the graft. The exception to this is rifampin, which remains fixed in Dacron prostheses after passive addition of the agent to aliquots of blood used to clot the interstices of porous Dacron grafts. This characteristic of rifampin is presumed to be caused by its poor water solubility. This potential infection resistance was challenged in a standard model of a canine infrarenal aortic graft by intravenous infusion of S. aureus organisms (10(7)) in the perioperative period. The grafts of five animals were preclotted with 9 ml of autogenous blood plus 1 ml of rifampin (60 mg/ml). A second group had similar procedures with 1 ml of cefazolin (238 mg/ml) substituted for the rifampin, and a control group had 1 ml of saline solution added to the 9 ml aliquot of blood. The animals were killed at 3 weeks and examined for clinically apparent infection. Rings of the graft material were also removed aseptically and cultured. All five grafts preclotted with cefazolin had clinical and culture evidence of infection (S. aureus), as did the grafts of three of the five control dogs. None of the grafts preclotted with rifampin was infected (p less than 0.05). Addition of rifampin to the blood used to clot the graft interstices appears to be a simple way of imparting graft resistance to perioperative sepsis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941596     DOI: 10.1067/mva.1986.avs0040005

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

Review 1.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Management of a Mycotic Aneurysm in a Patient with COVID-19: A Case Report.

Authors:  Muzammil H Syed; Mark Wheatcroft; Danny Marcuzzi; Hooman Hennessey; Mohammad Qadura
Journal:  Medicina (Kaunas)       Date:  2021-06-14       Impact factor: 2.430

3.  A Case Report on the Successful Treatment of Streptococcus pneumoniae-Induced Infectious Abdominal Aortic Aneurysm Initially Presenting with Meningitis.

Authors:  Yohei Kawatani; Yoshitsugu Nakamura; Yujiro Hayashi; Tetsuyoshi Taneichi; Yujiro Ito; Hirotsugu Kurobe; Yuji Suda; Takaki Hori
Journal:  Case Rep Surg       Date:  2015-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.